Piper Sandler Adjusts Bristol-Myers Squibb Price Target to $66 From $62, Maintains Overweight Rating
Piper Sandler has increased its price target for Bristol-Myers Squibb (BMY) to $66 from $62, while reaffirming its Overweight rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm for the pharmaceutical company. The article also lists other recent analyst adjustments and company news related to drug development and collaborations.
https://www.marketscreener.com/news/piper-sandler-adjusts-bristol-myers-squibb-price-target-to-66-from-62-maintains-overweight-rating-ce7e5bd9d08bf02d